Megado Minerals Limited (MEG)

Overview

XTL Biopharmaceuticals Ltd. is a pioneer in the field of biopharmaceuticals, focusing on the acquisition and development of novel pharmaceutical products aimed at treating autoimmune diseases. The company operates from its headquarters in Ramat Gan, Israel. Having initiated as Xenograft Technologies Ltd., it underwent a name change in July 1995 to better reflect its expanded focus and expertise in biopharmaceuticals. Since its inception in 1993, XTL Biopharmaceuticals Ltd. has committed itself to addressing the unmet medical needs of patients suffering from a range of autoimmune conditions through rigorous research and development initiatives.

Products and Services

• hCDR1

This lead drug candidate represents XTL Biopharmaceuticals Ltd.'s forefront innovation in the fight against autoimmune diseases. Currently in Phase II-ready status, hCDR1 is designed for the treatment of systemic lupus erythematosus (SLE) and Sjogren's syndrome, two challenging autoimmune conditions that affect millions worldwide. The development of hCDR1 showcases the company's dedication to utilizing advanced scientific research to create therapeutic options that can significantly improve patients' lives.

• Licensing Agreement with Yeda Research and Development Company Limited

A pivotal aspect of XTL Biopharmaceuticals Ltd.'s strategy for the development and commercialization of its lead compound, hCDR1, is its licensing agreement with Yeda Research and Development Company Limited. This partnership underscores the company's collaborative approach to innovation, enabling access to crucial intellectual property, research capabilities, and developmental milestones that are essential for the advancement and future success of hCDR1 across various indications beyond its current targets.